Digipath Inc. a leading provider of cannabis testing services through its DigiPath Labs subsidiary, recently began performing testing operations for clients at its Nevada-based laboratory and plans to aggressively expand its operations in 2016, according to CEO Todd Denkin and CSO Cindy Orser, Ph.D., in an exclusive interview with CannabisFN.
The company’s first cannabis testing facility opened in May of 2015 and has since acquired numerous customers, ran hundreds of tests, and generated revenue for shareholders. In addition, the company has focused on conducting basic research in the space and validating assays with Romer Labs and Medicinal Genomics. The overarching focus on robust testing for heavy metals, pesticides, microbials, and mycotoxins have set it apart within the industry.
Dr. Orser has also been instrumental in working with regulators to craft effective testing regulations in order to avoid the problems seen in Colorado and Oregon. For instance, she met with the Conference of Western Attorneys General earlier this year to discuss potential laws, while working Nevada regulators to explain best practices for the industry. The hope is to expand Nevada’s strict testing laws to other states that have legalized the drug.
GreenWave Advisors predicts that the cannabis testing industry will reach $850 million by 2020, processing a little more than five million pounds of marijuana. With the recent shakeout in the industry, DigiPath remains well positioned with its robust laboratory testing procedures, close relationships with clients, and groundbreaking research into bioactivity assays for patients, genetic fingerprints for strains, and other areas of the burgeoning industry.